Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arrow LionHeart

This article was originally published in The Gray Sheet

Executive Summary

Preliminary data review of 25 patients implanted with the left ventricular assist system shows the device is associated with tangible improvements in quality of life and has yet to fail or cause infection, according to notified body TUV Munich. However, TUV believes 10-15 patients will need to be added over the next six months to compare Arrow's trial to Thoratec's seminal 67-patient REMATCH trial of the HeartMate VE, which is now considered the benchmark for all future LVAS trials (1"The Gray Sheet" April 15, 2002, p. 17). The LVAS system will probably receive its European CE mark in early 2003, instead of June 2002, as the company had first predicted, due to the change in trial protocol (2"The Gray Sheet" March 11, 2002, p. 16)...

You may also be interested in...

CHF Device Trial Endpoints Clarification From FDA Requested

Thoratec's REMATCH trial of the HeartMate VE left ventricular assist device, designed to demonstrate improved survival versus optimal medical management, will not be generalizable to most congestive heart failure device trials, according to Mehmet Oz, MD, Columbia University

Arrow LionHeart LVAD Trial Progress Supports 13% Stock Gain In February

Continued clinical progress in the development of Arrow's LionHeart left ventricular assist device (LVAD) as a destination therapy helped sustain a 13.2% advance in the firm's stock price in February to $45.73

ECHA Deliberates On Final Microplastic Proposal As Beauty Industry’s Fate Hangs In Balance

A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts